FDA Underlines Seizure Risk With Dalfampridine in MS

Susan Jeffrey

Disclosures

July 23, 2012

July 23, 2012 — Based on postmarketing surveillance data, the US Food and Drug Administration is updating healthcare professionals on the risk for seizures in patients with multiple sclerosis (MS) who begin treatment with dalfampridine (Ampyra, Acorda Therapeutics, Inc).

Seizures are a known side effect of dalfampridine, which was approved in 2010 to improve walking in patients with MS, the FDA notes in a statement released today. However, "FDA's analysis identified postmarketing case reports of seizures associated with Ampyra at the labelled recommended dose, with many cases of seizures occurring within the first week of starting" treatment, the statement said.

FDA is also updating the dalfampridine drug label to clarify recommendations that kidney function should be assessed before treatment is started and monitored at least annually while treatment continues, even if serum creatinine levels appear to be normal. Patients who miss doses should not take extra doses, the statement adds, because this could increase seizure risk.

The "vast majority" of seizures occurred in patients with no prior history of seizures. Some patients had been taking other drugs that could have increased seizure risk or lowered the seizure threshold, the agency notes, but most patients were at least 50 years old with factors that put them at risk for mild renal impairment, the statement adds. "Potentially, age-related renal dysfunction and resultant increases in Ampyra plasma concentrations contributed to the risk of seizure," they write.

"Before starting treatment with Ampyra, renal function should be assessed," FDA notes. If creatinine clearance (CrCl) is unknown, it can be estimated using the Cockcroft-Gault equation (multiplied by 0.85 for women).

In a statement, Acorda Therapeutics reminds clinicians that these observations arise from a planned annual safety review, which is part of the risk evaluation mitigation strategy (REMS) for the drug. The current review looks at data reported between March 2010 and March 2011.

"These data showed no new safety signals related to seizure risk with Ampyra, and are consistent with the data from clinical trials of Ampyra," the Acorda statement notes. The FDA communication clarifies prescribing information and continues to recommend that physicians monitor kidney function and check for seizure activity, the company writes. "It also informs physicians and patients that the majority of seizures happened within days to weeks after starting the recommended dose and in patients having no history of seizures."

During the period reviewed, approximately 46,000 patients with MS filled at least 1 prescription for dalfampridine; among these, 82 reports of seizures were confirmed — a rate consistent with that seen in clinical trials, the statement notes. "The company does not expect any changes to the REMS program or postmarketing commitments as a result of this update."

Dalfampridine should not be used in patients with a history of seizures or in those who have moderate or severe renal impairment (CrCl of 50 mL/minute or less).

Those with a CrCl between 51 and 80 mL/minute are considered to have mild renal impairment and so are at greater risk of seizures with dalfampridine because of increased plasma levels of the drug. "The potential benefits of Ampyra treatment must therefore be carefully considered against the potential risk of seizures before using Ampyra in patients with mild renal impairment."

The maximum recommended dose of dalfampridine is 10 mg taken twice daily, 12 hours apart. Tablets should be taken whole and should not be divided, crushed, chewed, or dissolved, the statement notes.

Treatment should be discontinued permanently if a seizure occurs.

Dalfampridine is marketed in Europe by Biogen Idec Inc, under the brand name Fampyra. The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use issued a conditional approval for the drug in May 2011. A conditional approval, the EMA website notes, "is granted to a medicinal product that [fulfills] an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorization holder is likely to provide comprehensive clinical data at a later stage."

The full FDA safety communication can be found here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....